Trulieve (OTC: TCNNF) grants director 23,438 RSUs vesting by 2032

Rhea-AI Filing Summary

Trulieve Cannabis Corp. director Matthew J. Foulston reported an award of 23,438 subordinate voting shares in the form of restricted stock units. These RSUs were granted at no cash cost as equity compensation and increase his direct holdings to 34,767 shares after the transaction.

The footnote explains that each RSU converts into one subordinate voting share, vesting on the earliest of his service ending on the board, a change of control of Trulieve, or December 1, 2032. This is a routine compensation-related equity grant rather than an open-market purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Foulston Matthew J.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Subordinate Voting Shares	23,438	$0.00	--

Holdings After Transaction: Subordinate Voting Shares — 34,767 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Foulston Matthew J.

(Last) (First) (Middle)

C/O TRULIEVE CANNABIS CORP.

3494 MARTIN HURST ROAD

(Street)

TALLAHASSEE FL 32312

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Trulieve Cannabis Corp. [ TRUL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Subordinate Voting Shares	03/13/2026		A		23,438(1)	A	$0	34,767	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one Trulieve Cannabis Corp. ("Trulieve") subordinate voting share. The RSUs will vest on the earliest of (i) the end of the reporting person's service on the board of directors of Trulieve, (ii) a change of control of Trulieve, or (iii) December 1, 2032.

	/s/ Eric Powers, as Attorney-in-Fact	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Trulieve (TCNNF) report for Matthew J. Foulston?

Trulieve Cannabis Corp. reported that director Matthew J. Foulston received 23,438 restricted stock units representing subordinate voting shares. This equity award was recorded at a transaction price of $0.00 per share as compensation and is not an open-market buy or sell transaction.

How many Trulieve (TCNNF) shares does Matthew J. Foulston hold after this Form 4?

After the RSU grant, Matthew J. Foulston holds 34,767 subordinate voting shares directly. The 23,438 restricted stock units increase his reported ownership and will each convert into one share when they vest under the specified conditions in the award terms.

What are the vesting conditions for the 23,438 Trulieve (TCNNF) RSUs granted to Matthew J. Foulston?

The 23,438 restricted stock units vest on the earliest of three events: the end of Foulston’s service on Trulieve’s board, a change of control of Trulieve Cannabis Corp., or December 1, 2032, when any unvested RSUs would fully vest.

Is the Trulieve (TCNNF) RSU award to Matthew J. Foulston a market purchase?

No, the filing shows a grant or award acquisition, not a market purchase. The RSUs were issued at a stated price of $0.00 per share as part of director compensation, so no open-market buying or selling of Trulieve shares occurred in this transaction.

What type of security was granted to Matthew J. Foulston by Trulieve (TCNNF)?

Matthew J. Foulston received restricted stock units (RSUs), each representing a contingent right to one Trulieve subordinate voting share. These RSUs will convert into actual shares only when the vesting conditions are met, rather than providing immediate unrestricted share ownership.

How is Matthew J. Foulston’s Trulieve (TCNNF) ownership classified in this Form 4?

The ownership in this Form 4 is reported as direct. The transaction is coded as an acquisition through a grant or award, and there is no footnote indicating that another entity or trust holds the shares or that Foulston lacks voting or investment authority.